http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 06 Nov 2024 11:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html <p align="justify">OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona.</p> <p align="justify">The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS). Findings from both therapeutic and preventive applications support the platform’s potential in http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html Wed, 06 Nov 2024 11:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html <p align="justify">OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona.</p> <p align="justify">The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS). Findings from both therapeutic and preventive applications support the platform’s potential in http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html Wed, 06 Nov 2024 11:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html <p align="justify">OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona.</p> <p align="justify">The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS). Findings from both therapeutic and preventive applications support the platform’s potential in http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html Wed, 06 Nov 2024 11:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html <p align="justify">OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona.</p> <p align="justify">The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS). Findings from both therapeutic and preventive applications support the platform’s potential in http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html Wed, 06 Nov 2024 11:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html <p align="justify">OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona.</p> <p align="justify">The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS). Findings from both therapeutic and preventive applications support the platform’s potential in http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html Wed, 06 Nov 2024 11:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html <p align="justify">OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona.</p> <p align="justify">The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS). Findings from both therapeutic and preventive applications support the platform’s potential in http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+PEGS+Europe/23933695.html Wed, 06 Nov 2024 11:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html <p align="justify">OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”.<br/></p> <p align="justify">The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumours. The 20 year expiration date of this patent is January 5, 2037. Related patents were http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html Wed, 14 Aug 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html <p align="justify">OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”.<br/></p> <p align="justify">The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumours. The 20 year expiration date of this patent is January 5, 2037. Related patents were http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html Wed, 14 Aug 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html <p align="justify">OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”.<br/></p> <p align="justify">The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumours. The 20 year expiration date of this patent is January 5, 2037. Related patents were http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html Wed, 14 Aug 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html <p align="justify">OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”.<br/></p> <p align="justify">The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumours. The 20 year expiration date of this patent is January 5, 2037. Related patents were http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html Wed, 14 Aug 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html <p align="justify">OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”.<br/></p> <p align="justify">The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumours. The 20 year expiration date of this patent is January 5, 2037. Related patents were http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html Wed, 14 Aug 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html <p align="justify">OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”.<br/></p> <p align="justify">The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumours. The 20 year expiration date of this patent is January 5, 2037. Related patents were http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Issuance+of+Key+Patent+Covering+Individualized+Neoantigen+Based+Vaccines/23595688.html Wed, 14 Aug 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html <p align="justify">OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco.</p> <p align="justify">Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html Thu, 20 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html <p align="justify">OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco.</p> <p align="justify">Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html Thu, 20 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html <p align="justify">OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco.</p> <p align="justify">Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html Thu, 20 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html <p align="justify">OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco.</p> <p align="justify">Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html Thu, 20 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html <p align="justify">OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco.</p> <p align="justify">Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html Thu, 20 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html <p align="justify">OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco.</p> <p align="justify">Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+Updates+on+its+Inverse+Vaccine+Platform+at+FOCIS+2024+Meeting/23375552.html Thu, 20 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html <p align="justify">OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.<br/></p> <p align="justify">This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html Tue, 11 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html <p align="justify">OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.<br/></p> <p align="justify">This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html Tue, 11 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html <p align="justify">OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.<br/></p> <p align="justify">This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It http://www.streetinsider.com/Press+Releases/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html Tue, 11 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html <p align="justify">OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.<br/></p> <p align="justify">This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html Tue, 11 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html <p align="justify">OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.<br/></p> <p align="justify">This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html Tue, 11 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368 http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html <p align="justify">OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.<br/></p> <p align="justify">This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It http://www.streetinsider.com/Globe+Newswire/Nykode+Therapeutics+Announces+mRNA-LNP+Cancer+Vaccine+Demonstrates+Superior+Efficacy/23344200.html Tue, 11 Jun 2024 01:00:00 -0500 A.40151759 NYKD O.00050368